-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
CJC-1295 No DAC 5mg is a synthetic research peptide studied in relation to growth hormone-releasing hormone pathway research, GHRH receptor signalling, growth hormone axis models, IGF-1 pathway research and endocrine signalling studies.
CJC-1295 without DAC is commonly referred to as Modified GRF 1-29 or Mod GRF 1-29. The “No DAC” wording means this version does not include the Drug Affinity Complex associated with longer-acting CJC-1295 with DAC formulations. Research references generally describe the no-DAC version as a 29-amino-acid modified GHRH analogue, while CJC-1295 with DAC is a longer-acting albumin-binding analogue.
This product is supplied for laboratory research use only. It is not a medicine, supplement, growth hormone product, anti-ageing product, muscle growth product, fat loss product, recovery product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | CJC-1295 No DAC |
| Common research names | Modified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC |
| Size | 5mg |
| Product type | Research peptide |
| Research category | Growth Hormone Research / GHRH Analogue Research |
| Common research interest | GHRH receptor signalling, GH axis research, IGF-1 pathway models |
| Peptide type | Synthetic modified GHRH 1-29 analogue |
| DAC status | No DAC, no Drug Affinity Complex |
| Approximate peptide length | 29 amino acids |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, muscle growth, fat loss, anti-ageing or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| CJC-1295 No DAC | Synthetic GHRH analogue | Studied in relation to GHRH receptor and GH axis research |
| Modified GRF 1-29 | Modified growth hormone-releasing factor fragment | Common no-DAC naming used in research peptide contexts |
| No DAC structure | No Drug Affinity Complex | Distinguishes it from longer-acting CJC-1295 with DAC |
| 29-amino-acid peptide structure | Short GHRH analogue | Used in pulse-oriented GHRH pathway research models |
| Molecular weight | Often listed around 3367 Da for no-DAC Modified GRF 1-29 | Useful for laboratory concentration and molar calculation planning |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
CJC-1295 No DAC should not be treated as identical to CJC-1295 with DAC. Supplier documentation, CoA, sequence confirmation, salt form and batch testing should always be checked because marketplace naming can vary across “CJC-1295”, “CJC-1295 without DAC” and “Modified GRF 1-29” listings.
CJC-1295 No DAC is studied as a modified GHRH analogue. In research settings, GHRH analogue compounds are examined for how they interact with the GHRH receptor and influence downstream growth hormone axis and IGF-1 pathway models.
The no-DAC version is commonly discussed as shorter-acting than CJC-1295 with DAC because it lacks the Drug Affinity Complex designed for albumin binding. This makes no-DAC CJC-1295 better positioned as a Modified GRF 1-29 research peptide rather than a long-acting CJC-1295 DAC-style research peptide.
Published human clinical research on CJC-1295 mainly relates to the DAC-associated long-acting analogue, where sustained GH and IGF-1 changes were studied in controlled clinical settings. That clinical research should not be used as a direct claim for CJC-1295 No DAC research vials.
| Research Area | CJC-1295 No DAC |
| Main research category | GHRH analogue research |
| Common alternative name | Modified GRF 1-29 |
| Parent pathway context | Growth hormone-releasing hormone pathway |
| Common receptor interest | GHRH receptor signalling |
| Downstream research interest | GH axis and IGF-1 pathway models |
| DAC status | No Drug Affinity Complex |
| Research comparison | Often compared with CJC-1295 with DAC, Sermorelin and Ipamorelin |
| Evidence limitation | Published research is often extrapolated from broader GHRH analogue and DAC-associated CJC-1295 literature |
| Product limitation | Research use only, not approved for human use |
| Feature | CJC-1295 No DAC | CJC-1295 with DAC |
| Common research name | Modified GRF 1-29 | CJC-1295 DAC |
| DAC status | Does not include Drug Affinity Complex | Includes Drug Affinity Complex |
| Research positioning | Shorter GHRH analogue research | Longer-acting GHRH analogue research |
| Albumin-binding design | Not the same DAC albumin-binding design | Designed around extended albumin-binding behaviour |
| Common pathway | GHRH receptor and GH axis research | GHRH receptor and GH axis research |
| SEO risk | Confusing it with DAC form | Confusing it with no-DAC form |
| Human-use claim | Not appropriate | Not appropriate |
The no-DAC and DAC versions should be clearly separated in product titles, descriptions, slugs and internal links. This helps reduce customer confusion and avoids implying that research findings for one variant automatically apply to the other.
| Feature | CJC-1295 No DAC | Sermorelin |
| Research class | Modified GHRH 1-29 analogue | GHRH 1-29 analogue |
| Common structure context | Modified GRF 1-29 | GRF 1-29 amide |
| Main research interest | GHRH receptor, GH axis and IGF-1 pathway models | GHRH receptor and GH axis pathway research |
| Structural modification | Modified/tetrasubstituted GHRH analogue wording is commonly used | Generally discussed as the native 1-29 GHRH fragment analogue |
| Human-use claim | Not appropriate for research-use products | Only relevant to approved or regulated medicine contexts where applicable |
| Feature | CJC-1295 No DAC | Ipamorelin |
| Research class | GHRH analogue research peptide | Growth hormone secretagogue receptor research peptide |
| Main pathway | GHRH receptor pathway | Ghrelin receptor / GHSR pathway |
| Common research interest | GH axis and IGF-1 pathway research through GHRH signalling | GH secretagogue pathway research |
| Product pairing risk | Often discussed with Ipamorelin online | Often discussed with CJC-1295 online |
| Safer positioning | GHRH analogue research peptide | GHSR pathway research peptide |
| Human-use claim | Not appropriate | Not appropriate |
| Strength | Product Page Positioning |
| CJC-1295 No DAC 5mg | Lower-strength research vial for protocol-specific concentration planning |
| CJC-1295 with DAC 10mg | Separate DAC-containing variant for longer-acting GHRH analogue research |
| CJC-1295 No DAC + Ipamorelin 10mg | Research blend requiring separate blend-specific positioning |
CJC-1295 No DAC 5mg should not be treated as duplicate content for CJC-1295 with DAC or CJC-1295 + Ipamorelin blends. Each product page should have its own mechanism section, strength-specific concentration table, variant explanation and internal linking.
| Common Online Claim | Safer Research-Use Wording |
| Growth hormone boost | Studied in GHRH receptor and GH axis research models |
| Muscle growth | Not an approved or appropriate product claim |
| Fat loss | Not an approved or appropriate product claim |
| Anti-ageing | Not an approved or appropriate product claim |
| Better sleep | Not an approved or appropriate product claim |
| Recovery | Better framed as GH axis pathway research, not a human benefit |
| Bodybuilding | Not suitable for research-use product positioning |
| Natural GH pulses | Better framed as pulse-oriented GHRH pathway research models |
CJC-1295 No DAC 5mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for growth hormone enhancement, muscle growth, fat loss, anti-ageing, recovery, sleep, bodybuilding, performance enhancement, body transformation, hormone therapy or general wellness use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for CJC-1295 No DAC 5mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 5mg Vial | Final Concentration |
| 0.5mL | 10mg/mL |
| 1mL | 5mg/mL |
| 2mL | 2.5mg/mL |
| 2.5mL | 2mg/mL |
| 5mL | 1mg/mL |
| 10mL | 0.5mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities.
Before handling CJC-1295 No DAC 5mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised CJC-1295 No DAC peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Sequence or identity confirmation | Helps distinguish no-DAC Modified GRF 1-29 from DAC-containing CJC-1295 |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis, no-DAC status and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, no-DAC status, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Product identity unclear | Possible DAC/no-DAC confusion | Stop and confirm CoA before using |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Variant control | Store and label separately from DAC-containing CJC-1295 |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record product name, no-DAC status, concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules or administration guidance.
CJC-1295 No DAC 5mg is not supplied for human or animal administration. It is a laboratory research-use product only.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Variant confirmation | No DAC / Modified GRF 1-29 identity confirmation |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 5mg vial strength matches the approved research protocol |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded, storage conditions are not followed or DAC and no-DAC variants are confused.
Because CJC-1295 is commonly discussed online in relation to growth hormone, anti-ageing, bodybuilding, fat loss and recovery, product pages should avoid wording that could be interpreted as encouraging human self-use, injection, hormone manipulation or performance enhancement.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Confirm no-DAC status | Prevents confusion with CJC-1295 with DAC |
| Confirm peptide identity | Helps verify product accuracy |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Clearly separate research pathways from human benefit claims | Avoids unsafe or misleading product positioning |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a growth hormone booster | Creates human-use and compliance risk |
| Never make muscle growth or fat loss claims | Not an approved or appropriate product claim |
| Never make anti-ageing or recovery claims | Not an approved or appropriate product claim |
| Never imply hormone therapy use | Not suitable for a research-use product page |
| Never confuse no-DAC and DAC variants | They are different product formats |
| Never copy handling notes from unrelated peptide products | May create preparation or labelling errors |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 5mg | 0.5mL | 10mg/mL |
| 5mg | 1mL | 5mg/mL |
| 5mg | 2mL | 2.5mg/mL |
| 5mg | 2.5mL | 2mg/mL |
| 5mg | 5mL | 1mg/mL |
| 5mg | 10mL | 0.5mg/mL |
If a researcher adds 1mL of suitable research-grade diluent to a 5mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example.
CJC-1295 No DAC is a synthetic research peptide commonly discussed as Modified GRF 1-29. It is studied in relation to GHRH receptor signalling, growth hormone axis research and IGF-1 pathway models.
In research peptide contexts, CJC-1295 without DAC is commonly used to refer to Modified GRF 1-29 or Mod GRF 1-29. Because naming can vary, the CoA and supplier documentation should always be checked to confirm the exact peptide identity.
“No DAC” means the peptide does not include the Drug Affinity Complex associated with the longer-acting CJC-1295 with DAC format. This is important because DAC and no-DAC products should not be treated as interchangeable.
CJC-1295 No DAC is studied in relation to the GHRH receptor pathway, growth hormone axis signalling, IGF-1 pathway research and endocrine signalling models.
No. This research product is not approved or supplied for muscle growth, fat loss, anti-ageing, recovery, bodybuilding, hormone therapy, performance enhancement or human administration. It should be described only as a laboratory research product.
No. The no-DAC product is commonly positioned as Modified GRF 1-29, while CJC-1295 with DAC includes a Drug Affinity Complex. Product pages should clearly separate these two formats to avoid misleading customers.
No. CJC-1295 No DAC is a GHRH analogue research peptide, while Ipamorelin is usually discussed as a growth hormone secretagogue receptor pathway research peptide. They relate to different receptor pathways.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity, salt form, no-DAC status and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| CJC-1295 PubChem compound profile | Useful background on CJC-1295 identity, but no-DAC status must still be checked against CoA and supplier documentation. |
| Modified GRF 1-29 / CJC-1295 No DAC molecular overview | Useful background on no-DAC CJC-1295 as a 29-amino-acid Modified GRF 1-29 research peptide. |
| CJC-1295 no-DAC vs DAC variant discussion | Useful background on why DAC and no-DAC variants should be separated in product positioning. |
Research Use Only: CJC-1295 No DAC 5mg is supplied strictly for laboratory research purposes. It is not intended for human or animal consumption, injection, therapeutic use, cosmetic use, diagnostic use, growth hormone enhancement, hormone therapy, muscle growth, fat loss, anti-ageing, recovery, bodybuilding, body enhancement or performance enhancement. Information on this page is provided for research education and product handling context only. Always follow applicable laws, institutional procedures, supplier documentation and qualified laboratory protocols.
